Discussion about this post

User's avatar
Neural Foundry's avatar

Nice roundup! The Merus deal is definitly one of the more interesting ones from an M&A arbitrage perspective, especially with that Q1 2026 timeline. The spread has been pretty tight since announcment which tells you the market thinks this one is going to close smoothly. What I find fasinating about this one is Genmab is really betting on petosemtamab in head and neck being a blockbuster, not pricing in much for the rest of the pipeline. Could be a good buy if you think they're being too conservative on the colorectal indications.

Expand full comment

No posts